Get our Free Patent Expiration Newsletter

Serving leading biopharmaceutical companies globally:

McKinsey
Mallinckrodt
Harvard Business School
Dow
Express Scripts
Moodys

Last Updated: November 18, 2019

DrugPatentWatch Database Preview

Details for Patent: 7,858,643

See Plans and Pricing

« Back to Dashboard

Which drugs does patent 7,858,643 protect, and when does it expire?

Patent 7,858,643 protects XALKORI and is included in one NDA.

This patent has forty-eight patent family members in forty-two countries.

Summary for Patent: 7,858,643
Title:Enantiomerically pure aminoheteroaryl compounds as protein kinase inhibitors
Abstract: Enantiomerically pure compound of formula 1 ##STR00001## are provided, as well as methods for their synthesis and use. Preferred compounds are potent inhibitors of the c-Met protein kinase, and are useful in the treatment of abnormal cell growth disorders, such as cancers.
Inventor(s): Cui; Jingrong Jean (San Diego, CA), Funk; Lee Andrew (Oceanside, CA), Jia; Lei (San Diego, CA), Kung; Pei-Pei (San Diego, CA), Meng; Jerry Jialun (San Diego, CA), Nambu; Mitchell David (San Diego, CA), Pairish; Mason Alan (San Diego, CA), Shen; Hong (San Diego, CA), Tran-Dube; Michelle (La Jolla, CA)
Assignee: Agouron Pharmaceuticals, Inc. (San Diego, CA)
Application Number:11/212,331
Patent Claim Types:
see list of patent claims
Compound; Composition;

Drugs Protected by US Patent 7,858,643

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
Pf Prism Cv XALKORI crizotinib CAPSULE;ORAL 202570-001 Aug 26, 2011 RX Yes No   Start Trial   Start Trial Y Y   Start Trial
Pf Prism Cv XALKORI crizotinib CAPSULE;ORAL 202570-002 Aug 26, 2011 RX Yes Yes   Start Trial   Start Trial Y Y   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Patented / Exclusive Use >Submissiondate

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Merck
Dow
Harvard Business School
Express Scripts
Baxter
Moodys

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.